NTRA 169.36 (+0.88%)
US6323071042Medical Diagnostics & ResearchDiagnostics & Research

Natera (NTRA) Competitor Comparison

We are evaluating the key criteria listed to compare Natera (NTRA) against its competitors in the Diagnostics & Research industry.

Linearity 3 years - NTRA ranking 36 / 58

These are the competitors of Natera in the industry Diagnostics & Research ranked by linearity 3 years
1. Waters WAT
71.25
2. Laboratory Corp of America Holdings LH
53.37
3. Ortho Clinical Diagnostics Holdings OCDX
33.4
4. Quest Diagnostics DGX
22.39
5. PerkinElmer PKI
16.14
6. Danaher DHR
11.02
7. Syneos Health SYNH
10.68
8. Thermo Fisher Scientific TMO
10.11
9. Anixa Biosciences ANIX
8.26
10. Agilent Technologies A
8.24
11. Mettler-Toledo MTD
8.2
12. Qiagen QGEN
7.85
13. Heska HSKA
7.67
14. IQVIA Holdings IQV
6.91
15. Olink Holding OLK
6.67
16. Icon ICLR
6.27
17. Bioventus BVS
5.6
18. IDEXX Laboratories IDXX
5.21
19. Sotera Health SHC
5.21
20. Medpace Holdings MEDP
5.05
21. Exact Sciences EXAS
4.79
22. Myriad Genetics MYGN
4.54
23. Global Cord Blood CO
4.22
24. National Research NRC
4.18
25. DexCom DXCM
3.74
26. Charles River Laboratories CRL
3.42
27. Sera Prognostics SERA
3.12
28. CareDx CDNA
2.74
29. Enzo Biochem ENZ
2.69
30. Illumina ILMN
2.65
31. Psychemedics PMD
2.48
32. Neogen NEOG
2.42
33. NeoGenomics NEO
2.26
34. MDxHealth MDXH
2.22
35. Guardant Health GH
2.16
36. Natera NTRA
2.11
37. MaxCyte MXCT
2.1
38. Trinity Biotech TRIB
2.06
39. Twist Bioscience TWST
2.02
40. Fulgent Genetics FLGT
2.01
41. Interpace Biosciences IDXG
1.99
42. Neuronetics STIM
1.98
43. Precipio PRPO
1.86
44. Exagen XGN
1.82
45. DarioHealth DRIO
1.79
46. Organovo Holdings ONVO
1.79
47. Biodesix BDSX
1.78
48. Co-Diagnostics CODX
1.74
49. Personalis PSNL
1.73
50. Lantheus Holdings LNTH
1.7
51. bioAffinity Technologies BIAF
1.7
52. Prenetics Global PRE
1.65
53. Pacific Biosciences of California PACB
1.65
54. SeqLL SQL
1.48
55. Inotiv NOTV
1.4
56. Aspira Womens Health AWH
1.38
57. Meridian Bioscience VIVO
0.73
58. RadNet RDNT
0.33

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.